At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 278 enrolled
Drug / intervention
300 IR grass pollen allergen extract tablet +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Double-blind, Placebo-controlled, Multi-national, Multi-centre, Phase III Paediatric Study of the Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Administered as Allergen-based Tablets Once Daily to Children Suffering From Grass Pollen Rhinoconjunctivitis
In Brief
A Phase 3 clinical trial evaluating 300 IR grass pollen allergen extract tablet and Placebo tablet for Allergy. Completed, enrolled 278 participants across 1 site.
Detailed Summary
A phase III study to evaluate the efficacy and safety of SLIT for grass pollen allergens compared with placebo for reduction of symptoms and rescue medication usage in children.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergy
CountriesGermany
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2006
First PostedDec 2006
Primary CompletionSep 2007
TodayJul 2026
First PostedDec 8, 2006
Enrollment StartDec 1, 2006
Primary CompletionSep 1, 2007
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 19.6 years ago
Interventions
300 IR grass pollen allergen extract tabletdrug
One sublingual tablet daily during 4 months before pollen season and during pollen season
Placebo tabletdrug
One sublingual tablet daily during 4 months before pollen season and during pollen season